Serina Therapeutics, Inc. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Serina Therapeutics amended Steve Ledger's CEO employment agreement effective July 19, 2026, restating the original September 9, 2024 agreement. Ledger retains $500,000 annual base salary plus 50% target bonus; non-qualifying termination triggers 12 months base + pro-rated bonus severance and 12 months COBRA; change-of-control termination triggers 1.5× base + 1.5× bonus plus 18 months COBRA and 100% equity acceleration. Restrictive covenants include 2-year non-compete (global scope, POZ technology focus), 18-month non-solicitation/no-poach, perpetual confidentiality.
Why this rating
Routine CEO contract amendment restating existing terms; no material change disclosed. Severance and equity acceleration reflect standard market practices for $21.8M market-cap biotech CEO. Non-compete and vesting terms unchanged from original agreement.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.